tbuckley/cabot-search huggingface dataset:
Impact of CD3+ and CD34+ Doses in the Mobilized Peripheral Blood Stem Cell Grafts on the Outcome of Reduced-Intensity Conditioning Allogenic Transplantation from Matched Unrelated Donors for Acute Myeloid Leukemia – an Analysis from the Acute Leukemia Working Party of the EBMT
Authors: Tomasz Czerw, Myriam Labopin, Christoph Schmid, Jan J. Cornelissen, Patrice Chevallier, Didier Blaise, Jurgen H Kuball, Noel Milpied, Jean-Yves Cahn, Bruno Lioure, Nathalie Fegueux, Laurence Clement, Anna Sandstedt, Johan Maertens, Gaelle Guillerm, Dominique Bordessoule, Mohamad Mohty, Arnon Nagler
Journal: Blood (2014)
Prospective Changes of Cardiac and Hepatic Iron and Cardiac Function in Low and Intermediate-1 Risk MDS Patients
Authors: Alessia Pepe, Antonella Meloni, Giancarlo Carulli, Esther Natalie Oliva, Francesco Arcioni, Sergio Storti, Maria Giovanna Neri, Emanuele Grassedonio, Stefania Renne, Gennaro Restaino, Cristina Salvatori, Vincenzo Positano, Michele Rizzo
Journal: Blood (2014)
Changes in p53 Expression By Immunohistochemistry during Azacitidine Therapy in Patients with MDS Can Predict Overall Prognosis
Authors: Su Wai Maung, Niamh Strahan, Philomena O'Byrne, Sarah O'Dowd, John O'Loughlin, Ronan Desmond, Johnny McHugh, Michael Jeffers, Helen Enright
Journal: Blood (2015)
Patient perception of nighttime noise in the hospital setting.
Authors: Stephanie Alessandroni, Lynette Peterson
Journal: Journal of Clinical Oncology (2016)

258 Background: The national standard survey, Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS), measures the patient’s perspective on hospital care. One area that continually evokes sub-optimal results is the ‘quiet at night’ measurement. Our investigation explored the patient’s perception of nighttime “noise” in the hospital setting. Methods: Patients in our medical surgical/telemetry floors subjectively evaluated the noise level at night. An ethnographic interview method was utilized that was approved and standardized to prevent bias. Results were stratified and coded. Results: A total of 224 patients completed the process prior to any intervention to provide our hospital with a baseline understanding of the current state. We then utilized two evidenced-based approaches which have been shown to decrease a patient’s perception of noise: a sleep pack consisting of ear plugs, headphones, and a sleep mask, and one-on-one education on how to use the relaxation channel. Of the additional 101 patients who received this education, twenty-seven of these participants completed a second interview the following day, which allowed for comparison data to be compiled. By speaking with the patients, our investigation not only yielded information regarding the perception of noise level in their room, but additionally identified factors that were the cause of the noise. Although, our two interventions did not produce a positive change in noise level, it did provide valuable feedback and insight for quality initiatives. Conclusions: Noise level is a quality issue which needs to be continually addressed. Our interdisciplinary team, along with nursing leadership, intends to move forward with developing a plan to promote an optimal healing environment.
Phase I, open-label study of MEDI0680, an anti-programmed cell death-1 (PD-1) antibody, in combination with MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in patients with advanced malignancies.
Authors: Omid Hamid, Laura Quan Man Chow, Fatemeh Tavakkoli, Shannon Marshall, Matthew Joseph Gribbin, Joyson Joseph Karakunnel, Jhanelle Elaine Gray
Journal: Journal of Clinical Oncology (2015)

TPS3087 Background: The PD-1/PD-L1 pathway plays a key role in controlling T-cell activation and may be utilized by tumor cells to evade antitumor responses. Anti-PD-1 and anti-PD-L1 antibodies have shown acceptable safety profiles and clinical activity across a range of tumor types. MEDI0680 is a humanized IgG4κ mAb specific for human PD-1 that blocks PD-L1 and programmed cell death ligand-2 (PD-L2). Blocking both PD-L1 and PD-L2 may have more efficient blockade and may be more specific for different tumor groups in comparison to blocking either one alone. MEDI4736 is a human IgG1 mAb that blocks PD-L1 binding to PD-1 and CD80 with high affinity and selectivity. Anti-PD-1 and PD-L1 agents block distinct interactions contributing to immunosuppression, suggesting potential additive or synergistic effects. Preclinical data, including mouse models, support potential benefit for anti-PD-L1 and anti-PD-1 in combination. Methods: This phase I, multicenter, open-label study evaluates the safety of MEDI0680 in combination with MEDI4736 in patients with advanced malignancies (NCT02118337). Eligible patients ( ≥ 18 years) will have an Eastern Cooperative Oncology Group performance status of 0-1. The primary objectives are to assess safety and tolerability, and determine the maximum tolerated dose of MEDI0680 in combination with MEDI4736. Secondary objectives include assessment of antitumor activity (including objective response rate, disease control rate, duration of response, progression-free survival, and overall survival), pharmacokinetics, and immunogenicity of the combination. Exploratory objectives include an evaluation of biomarkers within the tumor microenvironment and their relationship to tumor response, identification of genetic predictors of response or resistance, and an assessment of patient-reported outcomes. Recruitment is ongoing, with a target enrollment of approximately 150 patients across 3 centers in the United States. Clinical trial information: NCT02118337.
Outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR in-frame deletions of exon 19 according to the size of the deletion.
Authors: M. Taron, C. Queralt, C. Mayo, I. de Aguirre, A. Gasco, A. Insa, R. Palmero, C. Camps, J. Sanchez, R. Rosell
Journal: Journal of Clinical Oncology (2010)

7549 Background: In-frame deletions of exon 19 n est around the LREA string of amino acids (aa) located between residu es 747-750 of the EGFR polypeptide. Although outcome to erlotinib has been associated with the pr esence of the exon 19 deletion, the potential influence of the number of aa deleted has not been previously examined. Methods: 118 NSCLC p with EGFR in-frame deletions in exon 19 were treated with erlotinib. EGFR deletions were detected in pretreatment biopsies by length analysis after PCR and confirmed by DNA sequencing. Outcome to erlotinib was correlated with the size of the deletion. Results: p were classified in 4 subgroups according to the number of aa deleted: 6 aa in 60 p, 7 aa in 10 p, 5 aa in 9 p, and other aa variations in 39 p. No differenc es were observed among the 4 subgroups according to gender, smoking history, PS, metastatic site (including brain, bone, liver, pleural or adrenal), or other clinical characteristics. R esponse rate was 74.5% in the 6-aa subgroup, 83.3% in the 7-aa subgroup; 88.9% in the 5-aa subgroup, and 82.4% in others (p = 0.67). Progression-free survival was 19 months (m), 14 m, 11 m and 13 m respectively (p = 0.97). Median survival was 31 m, not reached, 24 m and 28 m, r espectively (p = 0.97). The frequency of grade 3-4 skin toxicity was higher in the 7-aa subgroup (20%; p = 0.09), but no other differences in skin or gastrointestinal toxicity were observed. Conclusions: Although the size of the deletion did not predict differenc es in outcome to erlotinib, the efficacy of other novel targeted agents may prove to be influenced by the size of the deletion. In future studies of p with EGFR mutations, it would thus be advisable to report the exact position of the deletion and the number of aa deleted. No significant financial relationships to disclose.
A NOTCH1-Independant Pathway of c-Myc Oncogenesis in TAL1+ Human T-ALL.
Authors: B. Montpellier, B. Quilichini, J.M. Navarro, W.A. Dik, C. Formisano-Treziny, S. Roulland, C. Picard, C. Fossat, H. Chambost, J.J.M. van Dongen, E.A. Macintyre, A.W. Langerak, V. Asnafi, G. Michel, J. Gabert, B. Nadel
Journal: Blood (2007)
Safety and Efficacy of AG-221, a Potent Inhibitor of Mutant IDH2 That Promotes Differentiation of Myeloid Cells in Patients with Advanced Hematologic Malignancies: Results of a Phase 1/2 Trial
Authors: Eytan M. Stein, Courtney DiNardo, Jessica K. Altman, Robert Collins, Daniel J. DeAngelo, Hagop M. Kantarjian, Mikkael A. Sekeres, Amir T. Fathi, Ian W. Flinn, Arthur E. Frankel, Ross L. Levine, Bruno C. Medeiros, Manish R. Patel, Daniel Pollyea, Gail J. Roboz, Richard M. Stone, Ronan T. Swords, Martin S. Tallman, Katherine Yen, Eyal C. Attar, Qiang Xu, Alessandra Tosolini, Jay M. Mei, Anjan Thakurta, Robert D. Knight, Stéphane De Botton
Journal: Blood (2015)
Cisplatin navelbine versus cisplatin capecitabine in the treatment of metastatic breast cancer
Authors: T. Hashem, K. Kamal al-Din, N. Mobarek, T. Al-Said, S. Al-Hassanin
Journal: Journal of Clinical Oncology (2008)

12015 Background: Failure of anthracycline- and taxane-based chemotherapy in controlling patients with metastatic breast cancer is an increasing problem. Dealing with these groups of patients is a challenge as it is difficult to find other effective treatment options with acceptable toxicity. We conducted this prospective study to determine the efficacy and toxicity of two platinum-based chemotherapy (cisplatin-navelbine versus cisplatin-capecitabine) in patients with metastatic breast cancer who have been previously received anthracycline and/or taxane-based regimens. Methods: Forty patients with metastatic breast cancer previously treated with anthracyclines and/or taxanes were randomized to receive cisplatin 75mg/m2 on D1 plus navelbine 25mg/m2 on D1, 8 (group A) or cisplatin 75mg/m2 on D1 plus capecitabine 1750mg/m2 on D2–15 (group B) every 3 weeks. Results: The overall response rate (ORR) was 41% as a whole; group A showed higher ORR than group B (47.4% (with no complete responses) versus 36.8% (three CR and four partial responses)) and disease stabilized in 21.1% and 36.8% of women treated on groups A and B, respectively with statistically insignificant difference between both groups. Median duration of response, median time to progression (TTP) and median overall survival (OS) were 6, 9 & 4 months and 6, 10 & 16 months for groups A and B respectively. Hematologic toxicity was mild, with grade 3 neutropenia in 5 patients (25%) and grade 4 febrile neutropenia in 2 patients (10%) in group A. Severe acute or chronic non-hematologic adverse events were infrequent in both groups. There were no treatment related deaths. The mean of the total scores of quality of life was statistically significant between both groups in favor of group B. Conclusions: This study demonstrated that platinum-based chemotherapy has activity in the treatment of metastatic breast cancer with manageable and tolerable toxicity. Cisplatin/navelbine group showed a higher response rate in comparison with the cisplatin/capecitabine group with statistically insignificant difference. These data suggest that both groups offer results similar to taxanes alone or in combination with other drugs with less toxicity and costs. No significant financial relationships to disclose.
Cardiac Recovery During Long-Term Left Ventricular Assist Device Support
Authors: Omar Wever-Pinzon, Stavros G. Drakos, Stephen H. McKellar, Benjamin D. Horne, William T. Caine, Abdallah G. Kfoury, Dean Y. Li, James C. Fang, Josef Stehlik, Craig H. Selzman
Journal: Journal of the American College of Cardiology (2016)
Adolescents and Young Adults with Acute Lymphoblastic Leukemia Have Better Outcomes When Treated with Pediatric-Inspired Regimens - Systematic Review and Meta-Analysis of Comparative Trials
Authors: Ron Ram, Ofir Wolach, Liat Vidal, Anat Gafter-Gvili, Ofer Shpilberg, Pia Raanani
Journal: Blood (2011)
HematideTM, a Synthetic Peptide-Based Erythropoiesis Stimulating Agent (ESA), Assessed for Correction of Anemia in Oncology Patients Receiving Chemotherapy.
Authors: Lisa M. Pickering, Karel Cwiertka, Jacek Jassem, Jiri Petera, Ruth Pettengell, Rodryg Ramlau, Jiri Vorlicek, Rostislav Vyzula, Corina Andresen, Stephen Chang, Anne-Marie Duliege, Robert Leong, Richard Stead, Peter G. Harper
Journal: Blood (2006)
Mucosal Ecological Network of Epithelium and Immune Cells for Gut Homeostasis and Tissue Healing
Authors: Yosuke Kurashima, Hiroshi Kiyono
Journal: Annual Review of Immunology (2017)

The intestinal epithelial barrier includes columnar epithelial, Paneth, goblet, enteroendocrine, and tuft cells as well as other cell populations, all of which contribute properties essential for gastrointestinal homeostasis. The intestinal mucosa is covered by mucin, which contains antimicrobial peptides and secretory IgA and prevents luminal bacteria, fungi, and viruses from stimulating intestinal immune responses. Conversely, the transport of luminal microorganisms-mediated by M, dendritic, and goblet cells-into intestinal tissues facilitates the harmonization of active and quiescent mucosal immune responses. The bacterial population within gut-associated lymphoid tissues creates the intratissue cohabitations for harmonized mucosal immunity. Intermolecular and intercellular communication among epithelial, immune, and mesenchymal cells creates an environment conducive for epithelial regeneration and mucosal healing. This review summarizes the so-called intestinal mucosal ecological network-the complex but vital molecular and cellular interactions of epithelial mesenchymal cells, immune cells, and commensal microbiota that achieve intestinal homeostasis, regeneration, and healing.
Complete Haematological Response after Low Dose Rituximab in a Patient with Refractory Warm-Type Autoimmune Haemolytic Anaemia
Authors: Annalisa Peli, Michele Malagola, Carla Filí, Cristina Skert, Cesare Bergonzi, Francesco Zaja, Aldo M. Roccaro, Domenico Russo
Journal: Blood (2008)
The Proadhesive Properties of Multimerin in Supporting Cellular Adhesion: Evidence for RGD and Non-RGD Dependent Adhesive Mechanisms.
Authors: Frederic Adam, Shilun Zheng, Nilesh Joshi, Youko Suehiro, David S. Kelton, Amin Sandhu, Samira Jeimy, Catherine P.M. Hayward
Journal: Blood (2004)
The Prognostic Impact of the Mutational Profile in Patients with Myelofibrosis in the Era of the JAK1/JAK2-Inhibitor Ruxolitinib
Authors: Haifa Kathrin Al-Ali, Song-Yau Wang, Nadja Jaekel, Anne Koehler, Rainer Krahl, Karolin Hubert, Thoralf Lange, Martin Roskos, Rayak Stengel, Ines Kovacs, Schwabe Scarlett, Karoline Schubert, Kathrin Wildenberger, Melanie Schneider, Elisabeth Koehler, Dietger Niederwieser
Journal: Blood (2014)
Raman spectroscopy to distinguish progression stages in breast cancer
Authors: S. E. Clare, H. Neubauer, C. Schuetz, R. Kurek, E. Solomayer, D. Wallwiener, D. F. Dye, J. M. Zaleski, R. J. Goulet, T. Fehm
Journal: Journal of Clinical Oncology (2006)

10619 Background: The concept of early breast cancer detection has evolved to mean the discovery of a premalignant lesion or an early stage invasive lesion prior to metastasis. Therefore, methods must be developed to identify the actual primogenitors of cancer, those lesions which with certainty will progress to cancer. Currently, two technologies are employed for routine imaging of the breast: mammography and ultrasonography. Neither of these techniques can unequivocally distinguish between benign and malignant tissue limiting them to detection but not diagnosis. We hypothesize that differences in Raman spectra will enable the accurate discrimination of breast lesions one from one another and from normal breast epithelia. Therefore, preliminary studies were performed to investigate the potential of Raman spectroscopy. Methods: Cyropreserved breast tissue was selected, sectioned (10 μM) and stained with Hematoxylin and Eosin to verify the histologic diagnosis and to guide the acquisition of Raman spectra from a consecutive section (30 μM). This “analysis” section is mounted on Permanox (polyolefin; Nunc, Rochester, NY) over an area of the slide perforated with small holes (dia. 1mm) to provide the laser with direct access to the tissue without background Raman scattering from the polyolefin. Using a Raman microscope spectra were obtained from multiple areas of five breast tumors to address the reproducibility of spectral similarities across different tumors, to identify spectral differences between malignant and benign tissue, to identify spectral differences between invasive and ductal carcinoma in situ (DCIS) and to optimize the integration time. Results: In general, the spectral profiles for each tissue type are conserved with distinct differences in the predominance and peak widths of specific vibrations. Even in the absence of complex algorithms, malignant vs. benign tissue identification is possible. An analysis of the ability to reliably distinguish between invasive ductal carcinoma and DCIS will have to await additional spectra. A sound vibrational fingerprint of the tissue, consistent with that of the high signal/noise scan at 10 minutes, can be obtained within 30 seconds. Conclusions: Raman spectroscopy with short collection times shows promise and warrants further investigation. No significant financial relationships to disclose.
The use of patient-derived xenograft models for prioritizing therapeutic targets.
Authors: Clare L. Scott, Monique Topp, Alison Maree Hadley, Valerie Heong, Maria I Harrell, Orla McNally, Stephen B. Fox, Kunal Lodhia, Paul Haluska, David Bowtell, Elizabeth M. Swisher, Matthew Wakefield
Journal: Journal of Clinical Oncology (2015)

5579 Background: Treatment options for women with high-grade serous ovarian cancer (HGSC) remain limited. Defective DNA repair capability may underlie response to standard chemotherapy and to PARP inhibitor therapy1,2. Thus, molecular characterization of HGSC may indicate likely sensitivity or resistance to therapeutics. However, determining which potential targets actually drive tumor growth and should be prioritized for therapy is challenging. Pre-clinical HGSC cell lines have been shown to poorly reflect human disease3 and rarely contain DNA repair gene mutations4. In contrast, patient-derived xenograft (PDX) models provide relevant, accurate and tractable models for pre-clinical testing, representative of patient outcome5,6. Methods: A patient derived xenograft (PDX) cohort was generated from consecutive, treatment-naïve human HGSC and stratified according to DNA repair capability including BROCA sequencing7 and next generation sequencing by Foundation Medicine. In vivo response to standard chemotherapy with cisplatin was determined. Resistance to therapy was driven by re-treating relapsed PDX in vivo. Potentially “actionable” aberrations were targeted in vivo with relevant novel therapeutics. Results: To date, of 30 HGSC PDX studied, 11 contained defects in the DNA repair genes, BRCA1 or BRCA2 (9 had BRCA1/2 mutations, 2 had BRCA1 methylation) and another 3 PDX contained mutations in other DNA repair genes (FANCL, ATM, CHK2). All BRCA1/2-mutant PDX responded to platinum therapy. Dominant oncogenes (eg CCNE1, LIN28B, MYCN and BCL2) were overexpressed in platinum-refractory PDX. Potentially actionable targets were targeted in vivo with novel therapeutic strategies. Conclusions: As patient surrogates, PDX models represent a powerful tool for addressing individualized therapy. PDX are reliably generated from HGSC with DNA repair defects, not seen with cell lines. PDX with serial histologic, molecular, therapeutic annotation and clinical outcome data can be useful in assessing response to novel therapies. TCGA Nature 2011 Ledermann Lancet Oncology 2014 Domcke Nat Comms 2013 Stordal Mol Oncol 2013 Topp Molecular Oncology 2014 Weroha Clin Canc Res 2013 Walsh PNAS 2011
How much do Turkish women know about breast cancer prevention?
Authors: G. Atalay Basaran, D. Yilmaz, I. Bingol, U. Kiziltac
Journal: Journal of Clinical Oncology (2010)

e12038 Background: Early diagnosis is of paramount importance in reducing mortality from BC. We assessed the awareness of BC prevention in Turkish women with a crosssectional survey. Methods: Women > 20 yrs of age without cancer and who do not work in the healthcare completed our survey made up of 10 questions including the most important causes of BC, frequency of having mammography (M), breast self examination (BSE), the age for beginning first M, socioeconomic status (family history of cancer, level of education, marital status, the number of children, economic status) and the presence of comorbid diseases. Results: The median age of the 178 women was 40 (20-83). Education level was distributed as 31% primary school, 28% high school, 39% university. 21% were single, 70% had children, 62% had an occupation; the women with high/intermediate/low income were 18/61/22% of the population respectively. The most common sign of BC was recorded as a lump in the breast by 53% of the women. Familial/genetic factors, nutritional factors, use of estrogen were reported as the most common three causes of BC by the 65%, 23% and 20% of women respectively. Fifty-three percent of the women had regular BSE and it was significantly associated with age and marital status (p = 0.05, p = 0.02). Among women > 40 yrs , 48% had at least one M; 52% never had a M. Awareness of M as a screening tool was significantly associated with higher educational level (p = 0.05) .The age for beginning M was recorded as 20, 30, 40, 50 by 1%, 19%, 39%, 12% of the women respectively, 29% women did not know about it. Level of education, having an occupation and presence of comorbid diseases were significantly associated with awareness of screening with M (p = 0.00; p = 0.01.; p = 0.04) respectively. 44% women had a first degree relative with cancer, 16% of women had a relative with BC. Presence of a relative with cancer had no impact on the awareness of screening with M and BSE. Conclusions: The survey population have inadequate knowledge about development and prevention of BC. This isusue may even be worse in other parts of the country given our relatively well educated population with good socioeconomic status. Public health education and development of national screening programs are necessary to improve breast cancer care in Turkey. No significant financial relationships to disclose.